Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > CR going up!!!

<< Previous

Bullboard Posts

Next >>

Comment by enriquesuaveon Feb 01, 2021 8:37am

250 Views

Post# 32434653

RE:RE:RE:CR going up!!!

From memory, I believe only 4 of the first set of 12 have received a second treatment which was optimized. At 180 days we have 4 CR and 2 pending. The only 2 pending at day 180 are patients 13 &14 IMO. They also got optimized treatments. Looking amazing. What this shows is that the treatment works when given properly Maximum Bladder Volume used. If this is demonstrated after the next 11 patients, there will be no doubt in anyone and the Market that we got ourselves the Next Gold Standard. All IMO

fredgoodwinson wrote:

Apologies - others have received the optimised dose - this was the position before

‘2 out of the last 5 patients treated for the second time have been treated with the optimized Study II treatment, which will also be the case for the 2 patients that are pending their second treatment.’

but 13 & 14 will - uniquely to date - have received the optimised treatment ab initio and agreeing with Macer am optimistic as to the consequent outcomes.